2,375 results on '"Habermann, Thomas M."'
Search Results
2. Multiomic analysis identifies a high-risk signature that predicts early clinical failure in DLBCL
3. Defining primary refractory large B-cell lymphoma
4. Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatment
5. Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP
6. Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study
7. Follicular lymphoma B cells exhibit heterogeneous transcriptional states with associated somatic alterations and tumor microenvironments
8. Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapy
9. Incidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System Prophylaxis
10. Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy
11. Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma
12. Contributors
13. Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes
14. Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes
15. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma
16. Should All Patients With Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Receive Antibiotic Eradication Therapy for Helicobacter pylori?
17. Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis
18. Maintenance rituximab or observation after frontline treatment with bendamustine‐rituximab for follicular lymphoma
19. Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study
20. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma
21. A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome
22. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
23. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study
24. How I treat cardiovascular complications in patients with lymphoid malignancies
25. Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
26. Outcomes of patients with stage I–II Hodgkin lymphoma who had uniform pre-treatment staging with PET/CT and treatment with limited field radiation therapy after chemotherapy
27. Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy
28. Long-Term Follow-Up of the RESORT Study (E4402): A Randomized Phase III Comparison of Two Different Rituximab Dosing Strategies for Low–Tumor Burden Follicular Lymphoma
29. High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course
30. Elevated Serum Lactate in Patients With Lymphoma: It Is Not Always Infection
31. Risk for Significant Kidney Function Decline After Acute Kidney Injury in Adults With Hematologic Malignancy
32. PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts
33. Clinical manifestations of, diagnostic approach to, and treatment of neurolymphomatosis in the rituximab era
34. Outcomes of Autologous Stem Cell Transplant Consolidation in Primary Central Nervous System Lymphoma: A Mayo Clinic Experience
35. Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL
36. Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigation.
37. Indolent Lymphomas
38. Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?
39. Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials
40. Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial
41. Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes
42. Molecular Classification of Relapsed DLBCL Reveals Novel Biologic Subgroups
43. DEK Regulates B-Cell Proliferative Capacity and Is Associated with Aggressive Disease in Low-Grade B-Cell Lymphoma
44. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023
45. Evaluation of the International Prognostic Score (IPS‐7) and a Simpler Prognostic Score (IPS‐3) for advanced Hodgkin lymphoma in the modern era
46. Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma
47. Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial
48. Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015.
49. A genome-wide association study of marginal zone lymphoma shows association to the HLA region.
50. Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.